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Background: Ovarian tumors create a dynamic microenvironment that promotes angiogenesis and reduces
immune responses. Our research has revealed that threonyl-tRNA synthetase (TARS) has an extracellular angiogenic
activity separate from its function in protein synthesis. The objective of this study was to test the hypothesis that
TARS expression in clinical samples correlates with angiogenic markers and ovarian cancer progression.
Methods: Protein and mRNA databases were explored to correlate TARS expression with ovarian cancer. Serial
sections of paraffin embedded ovarian tissues from 70 patients diagnosed with epithelial ovarian cancer and 12
control patients were assessed for expression of TARS, vascular endothelial growth factor (VEGF) and PECAM using
immunohistochemistry. TARS secretion from SK-OV-3 human ovarian cancer cells was measured. Serum samples
from 31 tissue-matched patients were analyzed by ELISA for TARS, CA-125, and tumor necrosis factor-α (TNF-α).
Results: There was a strong association between the tumor expression of TARS and advancing stage of epithelial ovarian
cancer (p < 0.001). TARS expression and localization were also correlated with VEGF (p < 0.001). A significant proportion of
samples included heavy TARS staining of infiltrating leukocytes which also correlated with stage (p = 0.017). TARS was
secreted by ovarian cancer cells, and patient serum TARS was related to tumor TARS and angiogenic markers, but did not
achieve significance with respect to stage. Multivariate Cox proportional hazard models revealed a surprising inverse
relationship between TARS expression and mortality risk in late stage disease (p = 0.062).
Conclusions: TARS expression is increased in epithelial ovarian cancer and correlates with markers of angiogenic
progression. These findings and the association of TARS with disease survival provide clinical validation that TARS is
associated with angiogenesis in ovarian cancer. These results encourage further study of TARS as a regulator of the tumor
microenvironment and possible target for diagnosis and/or treatment in ovarian cancer.
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Although mortality rates have decreased for most gyneco-
logic malignancies, ovarian cancer remains the most lethal
gynecologic cancer and ranks fifth in cancer deaths among
women [1]. Critical issues contributing to poor prognosis
include the inability to detect early stage disease and the* Correspondence: karen.lounsbury@uvm.edu
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unless otherwise stated.capacity of ovarian cancer cells to manipulate the tumor
microenvironment [2-4]. The current serum biomarker
cancer antigen-125 (CA-125) is not a reliable indicator of
ovarian cancer in pre-menopausal women and its use in
combination with other screening techniques has not im-
proved survival [5].
Ovarian cancer is highly angiogenic, and our labora-
tory and others have correlated ovarian cancer prog-
ression with the expression of angiogenic signaling
molecules, including hypoxia-inducible factor (HIF-1α)
and vascular endothelial growth factor (VEGF) [6,7]. Aal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ance of secreted cytokines including tumor necrosis factor-
α (TNF-α) that exert both autocrine and paracrine effects
on inflammatory and vascular endothelial cells [8]. This
interaction network of secreted factors holds important
clues for future diagnostic and treatment targets. It is
therefore critical to continue advances in understanding
the underlying cell signaling associated with the developing
ovarian cancer microenvironment.
The study of threonyl tRNA-synthetase (TARS) as an
extracellular angiogenic factor was instigated by the ob-
servation that the TARS inhibitor borrelidin has an anti-
angiogenic effect [9]. Although the canonical function of
TARS is to charge threonine onto tRNA during protein
synthesis, it has been identified as an auto-antibody (PL-7)
target in myositis autoimmune disorders [10]. The etiology
of these diseases includes TNF-α signaling, and there is an
epidemiological linkage between myositis and several dif-
ferent cancers [11,12]. Moreover, we recently discovered
that TARS has direct extracellular angiogenic activity both
in vitro and in vivo through a mechanism that includes at-
traction of endothelial cells [13]. These lines of evidence
led to the hypothesis that TARS plays a role in the tumor
microenvironment and may be an indicator of progression
in angiogenic and/or inflammatory cancers.
Here we explored the relationship between TARS and
human ovarian cancer. We provide the first report that
levels of TARS in patient tumors and inflammatory cells
correlate with angiogenesis and stage of disease. The secre-
tion of TARS by ovarian cancer cells, its presence within
patient serum, and the negative relationship between tumor
TARS and mortality risk highlight the potential of TARS as
a target in the clinical management of ovarian cancer.
Methods
Database analysis
The SAGE anatomic viewer within the Cancer Gene Anat-
omy Project database (CGAP) (http://cgap.nci.nih.gov/
SAGE/Viewer?TAG=GCAGACATTG&CELL=0&ORG=
Hs&METHOD=SS10,LS10) was used to assess mRNA
expression levels of TARS within normal and malignant
tissues. The Gene Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/geoprofiles/40739453) was
used to search existing mRNA profiles related to ovarian
cancer patient studies [14]. The Human Protein Atlas
(http://www.proteinatlas.org/ENSG00000113407/cancer)
provided information about TARS and cancers within a
set of immunostained tissue arrays [15].
Ovarian patient study group
This research was approved by the University of Vermont’s
institutional review board (CHRMS 00–260, 01–026, 12–
004). Written informed consent for participation in the
study was obtained from all patients. The study groupconsisted of 70 patients diagnosed with epithelial ovar-
ian cancer at Fletcher Allen Health Care/University of
Vermont between 1999 and 2003. The control group
consisted of 12 women who underwent oophorectomies
that were identified as benign pathologies (See Additional
file 1: Table S1A). Ovarian tissue samples were fixed
with formalin and embedded in paraffin. Histological
subtype was according to the WHO classification and
stage was determined by FIGO criteria. Blood samples
were obtained from a subset of patients (6 control, 31
cancer) prior to surgery (See Additional file 1: Table S1B).
Serum was prepared by centrifugation and then cryopre-
served until use. Patient survival information was obtained
using the Fletcher Allen electronic health record system
(PRISM).
Immunohistochemistry (IHC)
Serial sections (5 μm) from each paraffin-embedded speci-
men were cut, transferred to slides, and then analyzed
using immunohistochemistry to measure the expression of
TARS, VEGF and PECAM (CD31) as in Wong et al. [6].
Immunoperoxidase staining was performed using the fol-
lowing antibodies: monoclonal anti-TARS (1:100 Novus,
NB H00006897-M01, clone 1A9), monoclonal anti-VEGF
(1:100 Santa Cruz Biotechnology, SC-7269), and monoclo-
nal anti-PECAM (1:40 anti-CD31, DAKO, M-0823). No
primary antibody was used as a negative control. TARS
antibody staining was optimized for the greatest range of
detection by testing multiple dilutions (1:50–1:300) using
benign and Stage 3 ovarian tumor sections. Secondary
antibody was DAKO Polymer–HRP goat anti-mouse IgG.
Cells were lightly counterstained with Mayers’ hematoxylin
and slides were dehydrated and then mounted using
Cytoseal-60. Images were obtained using an Olympus
BX50 light microscope coupled to a CCD camera and
Metamorph image capture software. For TARS and
VEGF, images were scored blindly by 2 different investi-
gators for expression level using a scale of 1–4, where 1
was no staining and 4 was intense staining.
Cultured cell experiments
SK-OV-3 human ovarian cancer cells were cultured in
McCoy’s media supplemented with 10% fetal bovine
serum as described in [16]. For secretion experiments,
cells were grown in 10 cm dishes and serum-starved for
24 h followed by treatment with 10 ng/ml TNF-α or
exposure to 2% O2 for 16 h. Media was collected and
concentrated 20-fold using Amicon® Ultra-4 centrifugal
filters. Cell membrane integrity was confirmed using the
lactate dehydrogenase assay CytoTox-ONE™. Cell lysates
(5%) and corresponding concentrated cell media (25%)
were separated by SDS-PAGE and analyzed by Western
blot for presence of TARS (1:1000 rabbit-anti-ThrRS,
Santa Cruz Biotechnology SC-98543) as described in
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lysates and to confirm that TARS found in the media
was not a result of cell lysis.
To measure relative mRNA levels, SK-OV-3 cells were
grown in 6-well dishes. After treatments, mRNA was ex-
tracted and purified using a Qiagen RNeasy® kit. Double
stranded cDNA was generated and relative mRNA levels
were quantified by RT-qPCR using Taqman® Assays on
Demand™ for TARS, VEGF, and interleukin-1β (IL-1β)
with β2 microglobulin as the reference gene (Applied
Biosystems). Values were determined by the comparative
CT method and presented as Rq (2ΔΔCT).
ELISA
ELISA was performed on 50 μl of SK-OV-3 cell media
or patient serum samples using commercially available
reagents to measure human TARS (Cusabio Biotech) or
TNF-α (R&D Systems Quantikine® HS ELISA). Values
were determined by comparing to a standard curve (0–
800 pg/ml for TARS, 0–32 pg/ml for TNF-α).
Statistical analysis
Statistical analysis was performed using SYSTAT software.
Significance between group averages was determined by
one way ANOVA followed by pair-wise multiple compari-
sons. Equal variance within the datasets was confirmed by
Bartlett Chi-square analysis. Relationships between vari-
ables were examined using Pearson correlations. Cox pro-
portional hazard models were used to analyze survival
outcomes. Multivariate Cox models were also generated
to consider the effects of stage grouping and year of diag-
nosis on the outcome.
Results
Database analysis of TARS expression in ovarian cancer
To establish a connection between TARS and human
ovarian cancer we first explored the available database re-
sources for existing information. According to the CGAP
mRNA database, TARS is over-expressed in select cancers
including ovarian (56 tags) and colon adenocarcinoma (35
tags) [17]. In tissue arrays displayed in the Human Protein
Atlas, TARS protein is moderately expressed in normal tis-
sues but is highly expressed in ovarian tumors (9 of 12)
[15]. Analysis of a GEO Profile dataset of ovarian cancer
samples revealed that TARS mRNA levels are significantly
upregulated in ovarian carcinoma and reduced in patients
treated with neoadjuvant carboplatin/paclitaxel chemo-
therapy (Figure 1, also see Additional file 2) (GEO acces-
sion GDS2785; published by Moreno et al. [18]). The
TARS levels also parallel the levels for VEGF in the same
group of patients. This pattern of expression was not seen
for seryl-tRNA synthetase (SARS) or tyrosyl-tRNA syn-
thetase (YARS), suggesting that overexpression is not a
characteristic of all amino-acyl tRNA synthetases (aaRS).These data provide support for investigating the role of
non-canonical signaling by TARS in the angiogenesis and
progression of ovarian cancer.
TARS expression in patient tumor samples is positively
correlated with stage of disease and angiogenic markers
To validate the clinical links suggested by the database
studies and the mechanistic links found in our angio-
genesis study, we measured TARS expression in tissue
sections from 70 human ovarian cancer specimens, of
which 59 had 10 year patient survival information and
31 had matching pre-surgical serum samples [5]. Be-
cause TARS has a protein synthesis function in all cells,
the antibody dilution for IHC was optimized to detect
only overexpressed TARS. Of note, normal fallopian
tube epithelium exhibited high TARS staining, but its
significance relative to transformation was outside the
scope of this study [19,20]. Analysis by Pearson correl-
ation matrix revealed a significant positive correlation
(p < 0.001) between increasing disease stage and TARS
staining intensity in ovarian tumor cells (Figure 2,
Table 1). Overexpressed TARS also co-localized with
VEGF (Figure 3) and was in proximity to areas of neo-
vascularization indicated by the endothelial marker
PECAM (CD31) (See Additional file 3A). These data re-
veal a novel link between TARS expression and ovarian
cancer and confirm an association between TARS and an-
giogenic potential in the ovarian cancer microenvironment.
TARS is overexpressed in infiltrating leukocytes within
ovarian tumors
In the process of scoring the tumor tissue, we observed
that many tumors (32 of 70) exhibited positive TARS stain-
ing in the cytoplasm of infiltrating leukocytes (Figure 3).
These cells were histologically identified as neutrophils
and plasma cells due to their chromatin characteristics
(See Additional file 3B). A significant correlation was
found between leukocyte TARS staining and both tumor
TARS and stage of disease (p = 0.017), however the regres-
sion coefficients were weaker and the association with
VEGF was not significant (Table 1). In light of the connec-
tion between TARS and immune responses, these data
may indicate a role for TARS in the immune cell response
to ovarian tumors.
TARS is secreted from ovarian cancer cells in response to
cell stress
Our previous observation that extracellular TARS promotes
endothelial cell migration and angiogenesis suggested that
TARS may be secreted by ovarian cancer cells as a cell
stress signaling response. The association between TARS
autoantibodies and a TNF-α-related autoimmune disorder
further supported this possibility. To measure TARS secre-
tion, cultured human ovarian cancer cells (SK-OV-3) were
Figure 1 TARS mRNA levels are increased in ovarian cancer and reduced by neo-adjuvant chemotherapy. Data were obtained from GEO
dataset GDS 2785. The study analyzed mRNA by GeneChip microarray in ovarian tissue from 10 patients with benign conditions, 9 patients with
untreated adenocarcinoma, and 24 patients with adenocarcinoma treated with carboplatin/taxol prior to surgery (+Chemo) [18]. Shown are
expression profile comparisons for A, TARS, B, VEGF, C, SARS and D, YARS. Differences between groups was significant for TARS and VEGF as
determined by ANOVA Kruskal Wallis analysis, *p < 0.0001 compared with benign, #p < 0.001 compared with carcinoma.
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followed by assessment of TARS in the media using
Western blot and a TARS-specific ELISA. As shown in
Figure 4A,B, TNF-α promoted an increase in TARS in the
cell media. The hypoxia response was more modest, but
significant by ELISA. TARS was not present in the media
due to cell lysis, as confirmed by a cytotoxicity assay and
the lack of β-tubulin in the media samples. The increase
in secretion was not a direct consequence of TARS tran-
scription or mRNA stabilization since hypoxia and TNF-α
treatments reduced TARS mRNA levels, whereas VEGF
and IL-1β were increased respectively (Figure 4C). Taken
together with our previous data, these findings suggest
that ovarian cancer cells generate extracellular TARS as
part of their cell stress signaling response.
Serum levels of TARS correlate with tumor levels of TARS
If the TARS level increases with stage of disease and it is
secreted in response to cell stress, it is possible that
TARS could provide value as a serum diagnostic for
ovarian cancer. Serum samples were available for a sub-
set of 6 controls and 31 patients with ovarian cancer that
had matched tumor samples in the TARS IHC analysis.ELISA values were determined for TARS and TNF-α.
Values for CA-125 were obtained from previous sero-
logical testing at diagnosis [21]. The TARS levels in pa-
tient serum samples ranged from 266–896 pg/ml. There
was a significant correlation between the patient serum
levels of TARS and the TARS tumor score, but levels
did not correspondingly increase with stage of disease,
(Figure 5, Table 1). These data suggest that TARS can
be detected in serum, and encourage its further study as
a potential indicator of ovarian cancer.
Because of the link between TNF-α and TARS secre-
tion by cultured ovarian cancer cells as well as the TNF-
α association with myositis, we predicted that the serum
levels for TARS would parallel those for TNF-α. The
TNF-α levels ranged from 0.145-12.0 pg/ml and levels
did not correlate with stage of disease or level of TARS
in tumors or serum (Table 1). When compared with
other cancer patient studies, the levels of TNF-α in our
study were lower in both controls and cancer patients
[22]. Thus, although no correlations were found between
TNF-α and TARS or ovarian cancer, more studies are
needed using additional samples to account for variabil-
ity and low levels of detection.
Figure 2 TARS expression increases with stage of ovarian cancer. A. Tissues were stained for TARS by immunohistochemistry and counter-
stained with Mayers’ hematoxylin. Images were scored blindly by 2 independent investigators and tumor identification was later confirmed
by a pathologist (SLM). Shown are 10x images from (1) normal ovary and examples of TARS score increasing with extent of disease (2–4),
Bar = 100 μm. B. Graph representing average scores where high stage is ≥ stage 3; statistical significance determined by one-way ANOVA. For
more detailed statistics, see Table 1 for Pearson’s Correlations. C. Shown is a graph of individual patient TARS tumor scores grouped according to
FIGO stage of disease (i.e. Stage 3.75 = FIGO 3C).
Table 1 Pearson Correlation Matrix for TARS expression in ovarian cancer patient samples
Stage TARS Tumor VEGF Tumor TARS Serum TNF-α Serum
r, p-value r, p-value r, p-value r, p-value r, p-value
TARS Tumor* 0.436, <0.001 0.448, <0.001 0.455, 0.003 0.129, 0.429
TARS Immune 0.296, 0.017 0.472, <0.001 0.165, 0.188 0.229, 0.167 0.164, 0.325
TARS Serum 0.233, 0.153 0.455, 0.003 0.298, 0.062 0.155, 0.269
*Numbers represent the correlation (r) and significance (p-value) for each set of variables when compared with TARS (tumor and immune cells scores or serum
pg/ml). Significant correlations are indicated in bold.
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Figure 3 TARS expression co-localized with VEGF and in leukocytes. Tissues were stained by IHC as in Figure 2. Shown are 40x images of
serial sections stained with (A,B) No primary Ab as a negative control (C,D) TARS or (E,F) VEGF. Bottom panels show examples of TARS staining
in infiltrating leukocytes. Bar = 50 μm. See Additional File 3 for supporting images.
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in late-stage disease
Cox proportional hazard models were used to assess the
relationship between TARS expression and survival within
the patient study group (Tables 2 and 3). Survival was
measured in years alive after diagnosis (range 0.5-14 yrs).
As expected there was an increase in mortality risk with
stage of disease and serum levels of CA-125. The Hazard
Ratio increased by 1.654 for each unit increase in stage.
There was no significant survival relationship to serum
levels of TNF-α or TARS. Surprisingly, TARS tumor ex-
pression was inversely related with mortality in advanced
stage tumors as reflected by a negative trend in the reg-
ression coefficient (−0.394, p = 0.101). A multivariate Cox
proportional hazard model was generated to adjust for
Stage and year of diagnosis (Table 3). The number of pa-
tients and events in Stage 0, 1 and 2 was very low, thus
they were grouped. This analysis strengthened the rela-
tionship between TARS and survival (−0.465, p = 0.062).
Because adjustment for differing Stage groupings and
diagnosis years did not impact the negative relationship
between survival and TARS expression the results are not
likely due an artifact of small sample sizes or patient
population.
Discussion
The goal of this study was to determine if there is a clin-
ical relationship between TARS and the progression and
angiogenic potential of human ovarian cancer. The data
reveal the first positive correlation between TARS tumor
expression and the progression of cancer. The overall
results of the evaluation of TARS in tumor, immune
cells, and serum provide strong support for a connectionbetween TARS and both angiogenesis and stage of ovar-
ian cancer. Furthermore, these data provide clinical re-
levance to our previous biologic observations of an
angiogenic function of TARS. The observed secretion of
TARS by ovarian cancer cells leads to a working model
for TARS signaling that includes stress-mediated release
of TARS that stimulates angiogenesis and alters the
ovarian tumor microenvironment.
TARS is a member of the aaRS enzyme family whose pri-
mary function is to catalyze ATP-dependent formation of
specific amino-acyl tRNAs, thus maintaining fidelity during
protein translation [23]. Several aaRSs have been associated
with non-canonical cell signaling related to inflammation,
cell migration, and angiogenesis [24-30]. Those aaRSs asso-
ciated with angiogenesis include tyrosyl-tRNA synthetase,
which exhibits extracellular angiogenic activity, and
seryl-tRNA synthetase, which acts in the nucleus to
regulate VEGF expression during vascular development
[26,29]. Unlike TARS, these aaRSs were not upregulated
in ovarian cancer according to the mRNA or protein
database analyses. The selective association of TARS
with ovarian cancer suggests that its extracellular activ-
ity may be specifically important in the regulation of the
ovarian tumor microenvironment.
Angiogenesis has emerged as a critical component of
the tumor microenvironment, and anti-angiogenic therap-
ies for cancers have had success due to the reliance of
many cancers on new vessels and the poor prognosis asso-
ciated with cancers that have advanced angiogenesis [31].
Anti-angiogenic therapies for ovarian cancer have shown
effectiveness in clinical trials using the VEGF inhibitor
bevacizumab, especially when combined with the standard
chemotherapy regimen (paclitaxel and carboplatin) [32].
Figure 4 TARS is secreted by SK-OV-3 ovarian cancer cells.
(A) SK-OV-3 cells were treated with TNF-α (50 ng/ml) or exposed to
2% O2 for 24 h where indicated. Media was concentrated 20-fold to
accommodate 25% onto the gel and compared to 5% of the cell
lysate. Shown is a representative Western blot probed for TARS and
β-tubulin, n = 4. (B) Cells were treated as in (A). After 24 h the level
of TARS in the supernatant was determined by ELISA, *p < 0.05,
n = 3. Cell membrane integrity was confirmed using the lactate
dehydrogenase assay CytoTox-ONE™ and by lack of β-tubulin in
media samples. (C) Relative mRNA levels for TARS, VEGF and IL-1β
were determined by RT-qPCR following treatment as in (A);
*p < 0.001, **p < 0.0001, n = 4.
Figure 5 Correlation of TARS levels detected in serum with
TARS expression in ovarian cancer. Graphs represent scatter dot
plots (mean ± SD) of patient data for TARS serum levels against
(A) Stage of cancer and (B) TARS tumor tissue score. The correlation
(r-value) and p-values were calculated by a Pearson correlation
matrix (see Table 1).
Table 2 Hazard ratios for the association of TARS with
mortality using univariate Cox proportional hazard
models
Parameter n Cox coefficient SEM Hazard Ratio p-value
Stage 59 0.503 0.211 1.654 0.017
CA-125 35 0.412 0.155 1.510 0.008
TNF-α (pg/ml) 37 0.520 0.318 1.682 0.102
TARS (pg/ml) 37 0.281 1.272 1.324 0.825
TARS tumor 59 −0.394 0.240 0.674 0.101
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ovarian cancer, treatment complications and lack of suc-
cess in some patients demonstrate a clear need for more
ovarian-specific angiogenic targets. We propose that
TARS is an important angiogenic molecule that exhibits
extracellular signaling in ovarian cancer cells only under
conditions of metabolic stress. An agent that exclusively
targets extracellular TARS thus has the potential to pro-
vide an anti-cancer therapy that is effective and more spe-
cific than existing treatments.
The finding that TARS is secreted by ovarian cancer
cells in response to stress signaling is supported by the
Exocarta proteomics database, where TARS is on the list
of exosomal proteins released from bladder cancer cells,and ovarian cancer cells [33,34]. An exosome mechanism
for TARS secretion would be consistent with other signal-
ing proteins that regulate the extracellular matrix and are
overexpressed in cancer including heat shock protein 90
(HSP90), plasminogen activator inhibitor-1 (PAI-1) and
caveolin-1 (cav-1) [35-37]. Although the correlation be-
tween serum TARS and stage of disease failed to reach
significance, its presence at detectable levels and trend
Table 3 Multivariate Cox proportional hazard model for TARS tumor score
Variable Cox coefficient SEM Hazard ratio (95% CI) p-value
Stage grouping (0–2, 3, 4) 0.742 0.304 2.100 (1.161-3.80) 0.015
Year of Dx (1998–2001) 0.322 0.199 1.380 (0.936-2.03) 0.105
TARS tumor −0.465 0.249 0.628 (0.387-1.02) 0.062
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value as an ovarian cancer diagnostic.
Two unexpected discoveries were the findings that
TARS is overexpressed in infiltrating leukocytes within
ovarian tumors and that mortality risk is slightly reduced
for patients with high expression of TARS within their
tumors. TARS has previously been associated with auto-
immune disorders because it is the target for the auto-
antibody PL-7 in myositis disorders [12]. A specific role
for TARS in immune cell signaling has not been re-
ported, however several other aaRS enzymes exert im-
mune cell functions [10] and TARS is among B cell
proteins secreted in exosomes [38]. It is possible that the
improved survival associated with TARS expression is
related to its effects on inflammatory cell signaling that
reduce the support of the microenvironment. This possi-
bility is supported by evidence that infiltrating immune
cells in the context of high vascularity improves survival
in high grade serous ovarian cancer [39]. Alternatively,
the signaling through TARS may improve the suscep-
tibility of tumors to chemotherapy, similar to the im-
proved response of ovarian tumors expressing p53
mutations [18]. The antigenic properties of TARS and
the known role for immune cell signaling in angiogen-
esis encourage future study of TARS in immune cell re-
sponses to ovarian tumors.Conclusions
Taken together, the results of this study demonstrate that
TARS expression is significantly increased in human epi-
thelial ovarian cancer and relates to angiogenic markers
and stage of disease. Opposing correlations of TARS with
stage vs. survival suggest a complex role for TARS in
tumor progression. We propose that TARS is secreted by
tumor cells in response to metabolic stress or cytokine sig-
naling, which then affects the microenvironment through
vascular endothelial and immune cell responses. The limi-
tations of this study include the number of patient samples
and the IHC scoring technique. These weaknesses are bal-
anced by the strength of the information for each patient
and the ability to distinguish tumor staining within sec-
tions. The selectivity of TARS overexpression in ovarian
cancer and its presence in patient serum samples encour-
ages further study of TARS as a diagnostic or therapeutic
target.Additional files
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Additional file 2: Correlative mRNA levels of TARS and VEGF in
ovarian cancer patients.
Additional file 3: Images to supplement Figure 3.
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